Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis October 19, 2020 - NYSE Companies 0 Bay Street News » View More News for October 19, 2020